Q-omics provides the consensus-scored TCEA3 profile across patient tissues and cancer cell-line models. TCEA3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TCEA3 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, TCEA3 protein abundance shows 22,060 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, and LSCC as cancer lineages where TCEA3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCEA3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCEA3 survival associations across molecular data types. TCEA3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCEA3 RNA expression–survival associations across cancer types. High TCEA3 expression shows unfavorable associations in LGG, but favorable associations in HNSC, MESO, KIRC, KIRP and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TCEA3 RNA expression.
This table summarizes TCEA3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TCEA3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCEA3 shows lower tumor expression in HNSC, KICH, COAD, STAD and UCEC and higher tumor expression in KIRC. The HNSC box plot shows higher TCEA3 RNA expression in normal versus tumor tissue (log2 FC = −1.592, t-test p < 0.001).
This table shows molecular features associated with TCEA3 in patient tissues and cancer cell lines. In patient samples, TCEA3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TCEA3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
